Description:The chemical substance (S)-g-fitinib, with the CAS number 1374356-45-2, is an enantiomer of gefitinib, a well-known tyrosine kinase inhibitor primarily used in the treatment of non-small cell lung cancer (NSCLC). This compound selectively targets the epidermal growth factor receptor (EGFR), inhibiting its activity and thereby interfering with the signaling pathways that promote tumor growth and proliferation. (S)-g-fitinib exhibits a specific stereochemistry that may influence its pharmacological properties, including its potency, efficacy, and side effect profile compared to its racemic counterpart. The substance is characterized by its molecular structure, which includes a quinazoline core, and it is typically administered in oral form. Its solubility, stability, and bioavailability are critical factors that affect its therapeutic application. As with many targeted therapies, understanding the pharmacokinetics and pharmacodynamics of (S)-g-fitinib is essential for optimizing treatment regimens and improving patient outcomes in oncology.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.